U01CA058211 (BRENNER, MALCOLM K)Sep 30, 1992 - Sep 29, 1996 NIH TREATMENT OF NEUROBLASTOMA WITH IL2 TRANSDUCED TUMOR Role: Principal Investigator |
|
R01CA075014 (BRENNER, MALCOLM K)Sep 1, 1997 - Jun 30, 2002 NIH ACTIVITY OF LYMPHOTACTIN IN CHILDHOOD MALIGNANCY Role: Principal Investigator |
|
R01CA078792 (BRENNER, MALCOLM K)Sep 30, 1998 - Jul 31, 2004 NIH THERAPEUTIC EFFECTS OF CD40L IN ACUTE LYMPHOBLASTIC LEUK Role: Principal Investigator |
|
R21CA082101 (BRENNER, MALCOLM K)Aug 6, 1999 - Jun 30, 2001 NIH CD45 ANTIBODY EFFECT ON NORMAL AND MALIGNANT HEMOPOIESIS Role: Principal Investigator |
|
R21CA093069 (BRENNER, MALCOLM K)May 1, 2001 - Apr 30, 2004 NIH Haploidentical Allogeneic Transplantation Role: Principal Investigator |
|
U42RR016578 (BRENNER, MALCOLM K)Sep 30, 2001 - Aug 31, 2007 NIH ADENOVIRAL VECTOR PRODUCTION AT BAYLOR Role: Principal Investigator |
|
R13DK062214 (BRENNER, MALCOLM K)Jun 1, 2002 - Jun 30, 2003 NIH 5th Annual Meeting, American Society of Gene Therapy Role: Principal Investigator |
|
R21CA108143 (BRENNER, MALCOLM K)Apr 1, 2004 - Mar 31, 2006 NIH Combined CTL and CD45 antibody for nasopharyngeal carci* Role: Principal Investigator |
|
U54HL081007 (BRENNER, MALCOLM K)Sep 30, 2005 - Aug 31, 2011 NIH Improving the safety and efficacy of cell therapies Role: Principal Investigator |
|
P50CA126752 (HESLOP, HELEN E)Apr 1, 2007 - Aug 31, 2022 NIH SPORE in Lymphoma Role: Co-Principal Investigator |